Allist Pharmaceuticals

Fineline Info & Tech (Flcube.com) provides you with comprehensive information about Allist Pharmaceuticals details on the company, its pharmaceuticals, policies, deals, healthcare enterprises, research and development, hospitals, legal patents, and internet healthcare. More information about Allist Pharmaceuticals please access flcube.com
Fineline Info & Tech (Flcube.com) provides you with comprehensive information about Allist Pharmaceuticals, including details on the company, its pharmaceuticals, policies, deals, healthcare enterprises, research and development, hospitals, legal patents, and internet healthcare.

Brii Biosciences Launches BRiSC Bispecific siRNA Platform – Dual‑Target RNAi Engine to Advance Next‑Generation RNA Therapeutics in Prevalent Diseases
CompanyR&D

Brii Biosciences Launches BRiSC Bispecific siRNA Platform – Dual‑Target RNAi Engine to Advance Next‑Generation RNA Therapeutics in Prevalent Diseases

Brii Biosciences Limited (HKG: 2137) announced the launch of its proprietary BRiSC (Bispecific RNAi iSilenCing) small interfering RNA (siRNA) drug discovery platform, designed to advance the development of next‑generation ribonucleic…

AbbVie's RINVOQ Wins NMPA Approval for Severe Alopecia Areata – Ninth Indication in China Three Months After EU Clearance

AbbVie’s RINVOQ Wins NMPA Approval for Severe Alopecia Areata – Ninth Indication in China Three Months After EU Clearance

CSPC Pharmaceutical's Trispecific Antibody SYS6088 Wins NMPA Clinical Trial Approval – PD‑1/VEGFA/CTLA‑4 Candidate Targets Advanced and Metastatic Solid Tumors

CSPC Pharmaceutical’s Trispecific Antibody SYS6088 Wins NMPA Clinical Trial Approval – PD‑1/VEGFA/CTLA‑4 Candidate Targets Advanced and Metastatic Solid Tumors

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Allist's Furmonertinib Granted Priority Review for EGFR Exon 20 NSCLC in China
CompanyDrug

Allist’s Furmonertinib Granted Priority Review for EGFR Exon 20 NSCLC in China

CStone Pharmaceuticals Receives NMPA Approval for Local Production of Gavreto in China
CompanyDrug

CStone Pharmaceuticals Receives NMPA Approval for Local Production of Gavreto in China

Jacobio Pharma's Glecirasib Approved by NMPA for KRAS G12C+ NSCLC
CompanyDrug

Jacobio Pharma’s Glecirasib Approved by NMPA for KRAS G12C+ NSCLC

Abbisko Therapeutics and Allist Pharmaceuticals Partner on KRAS-G12C NSCLC Combination Therapy
CompanyDeals

Abbisko Therapeutics and Allist Pharmaceuticals Partner on KRAS-G12C NSCLC Combination Therapy

NewCo Model: China's Innovative Drug Companies' New Transaction Mode in Capital Winter
CompanyDeals

NewCo Model: China’s Innovative Drug Companies’ New Transaction Mode in Capital Winter

Allist Pharmaceuticals Gains NMPA Approval for Furmonertinib Clinical Study
CompanyDrug

Allist Pharmaceuticals Gains NMPA Approval for Furmonertinib Clinical Study

CompanyDeals

Jacobio Pharma Receives RMB 172 Million Milestone Payment from Allist Pharmaceuticals

CompanyDrug

Allist Pharmaceuticals’ EGFR Inhibitor AST2303 Approved for Clinical Trial in NSCLC by NMPA

Show More